Literature DB >> 22202971

The protective effects of metyrosine, lacidipine, clonidine, and moxonidine on kidney damage induced by unilateral ureteral obstruction in rats.

Murat Yigiter1, Abdullah Yildiz, Beyzagul Polat, Hamit Hakan Alp, Osman Nuri Keles, Ahmet Bedii Salman, Halis Suleyman.   

Abstract

PURPOSE: To investigate the effects of metyrosine, lacidipine, clonidine, and moxonidine on the renal damage in rats with unilateral ureteral ligation by examining the histological evidence of parenchymal damage and tubular dilatation, as well as biochemical changes indicating cell membrane damage and DNA oxidation.
METHODS: Thirty-six albino Wistar rats were randomly divided into six equal groups: a healthy (intact) group, a unilateral ureteral ligation (control) group, and four drug treatment groups given metyrosine (50 mg/kg), lacidipine (2 mg/kg), clonidine (0.075 mg/kg), or moxonidine (0.2 mg/kg), respectively, for 10 days. The latter five groups underwent ligation of the left ureter. Ten days after the operation, we removed both kidneys from each rat in the control and drug treatment groups for renal pathological and biochemical [malondialdehyde (MDA), total glutathione, 8-hydroxy-2-deoxyguanine (8-OH-Gua)] examinations. Spectrophotometric assays were used to detect the malondialdehyde and total glutathione levels of the renal tissue. High-performance liquid chromatography was used to measure the 8-hydroxy-2-deoxyguanine levels.
RESULTS: When the drug treatment groups were compared with the control group, the drug treatment groups' total glutathione level was higher and their malondialdehyde level was lower than that of the control group (P < 0.05), especially in the clonidine group (P < 0.0001). The 8-hydroxy-2-deoxyguanine levels of the drug treatment groups, except the lacidipine group, were significantly lower than that of the control group (P < 0.0001). There was no significant difference between the contralateral kidneys of the treatment groups and control group, according to the biochemical results. As revealed via light microscopy, clonidine and moxonidine treatment significantly reduced the tubular and glomerular damage, as well as the tubular dilation. The interstitial inflammation of the kidneys in the lacidipine group was higher than that of the other treatment groups. However, the apoptotic cell count was at a high level in both the lacidipine and metyrosine groups. The increase in the collagen content was most pronounced in the lacidipine and metyrosine groups. An examination of the contralateral kidneys showed no marked pathological findings.
CONCLUSIONS: The use of a direct or indirect α2-adrenergic receptor agonist for the temporary treatment of unilateral ureteral obstruction-induced renal damage may be important for preventing renal structural injury. A more advanced study is necessary to determine the mechanisms underlying the protective effects of these drugs with regard to renal damage in ureteral obstruction.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22202971     DOI: 10.1007/s00595-011-0074-8

Source DB:  PubMed          Journal:  Surg Today        ISSN: 0941-1291            Impact factor:   2.549


  45 in total

1.  Estimation of total, protein-bound, and nonprotein sulfhydryl groups in tissue with Ellman's reagent.

Authors:  J Sedlak; R H Lindsay
Journal:  Anal Biochem       Date:  1968-10-24       Impact factor: 3.365

2.  Inhibition of dopamine synthesis in chronic schizophrenia. Clinical ineffectiveness of metyrosine.

Authors:  H A Nasrallah; E F Donnelly; L B Bigelow; L Rivera-Calimlim; A Rogol; S Potkin; F P Rauscher; R J Wyatt
Journal:  Arch Gen Psychiatry       Date:  1977-06

3.  Atorvastatin ameliorates renal tissue damage in unilateral ureteral obstruction.

Authors:  Yasunori Mizuguchi; Akira Miyajima; Takeo Kosaka; Takako Asano; Tomohiko Asano; Masamichi Hayakawa
Journal:  J Urol       Date:  2004-12       Impact factor: 7.450

4.  Fluvastatin suppresses oxidative stress and fibrosis in the interstitium of mouse kidneys with unilateral ureteral obstruction.

Authors:  T Moriyama; N Kawada; K Nagatoya; M Takeji; M Horio; A Ando; E Imai; M Hori
Journal:  Kidney Int       Date:  2001-06       Impact factor: 10.612

5.  Role of adrenal gland hormones in antiinflammatory effect of calcium channel blockers.

Authors:  Halis Suleyman; Zekai Halici; Ahmet Hacimuftuoglu; Fatma Gocer
Journal:  Pharmacol Rep       Date:  2006 Sep-Oct       Impact factor: 3.024

6.  Indirect role of beta2-adrenergic receptors in the mechanism of anti-inflammatory action of NSAIDS.

Authors:  H Suleyman; Z Halici; E Cadirci; A Hacimuftuoglu; H Bilen
Journal:  J Physiol Pharmacol       Date:  2008-12       Impact factor: 3.011

7.  Renal impairment and its reversibility following variable periods of complete ureteric obstruction.

Authors:  R L Fink; D T Caridis; R Chmiel; G Ryan
Journal:  Aust N Z J Surg       Date:  1980-02

Review 8.  Nimesulide is a selective COX-2 inhibitory, atypical non-steroidal anti-inflammatory drug.

Authors:  H Suleyman; E Cadirci; A Albayrak; Z Halici
Journal:  Curr Med Chem       Date:  2008       Impact factor: 4.530

9.  Gastric lesion-preventing or -potentiating activity of clonidine in rats.

Authors:  P Del Soldato
Journal:  Jpn J Pharmacol       Date:  1986-06

10.  Central sympatholytic therapy has anti-inflammatory properties in hypertensive postmenopausal women.

Authors:  Maritta K Pöyhönen-Alho; Karin Manhem; Per Katzman; Aleksandras Kibarskis; Riitta L Antikainen; Risto U Erkkola; Jaakko O Tuomilehto; Pertti E Ebeling; Risto J Kaaja
Journal:  J Hypertens       Date:  2008-12       Impact factor: 4.844

View more
  2 in total

Review 1.  Tissue damage and oxidant/antioxidant balance.

Authors:  Abdullah Kisaoglu; Bunyamin Borekci; O Erkan Yapca; Habib Bilen; Halis Suleyman
Journal:  Eurasian J Med       Date:  2013-02

2.  The effect of coenzyme Q and selenium on kidney in rats with partial unilateral ureteral obstruction.

Authors:  Mustafa Koray Kırdağ; Devrim Tuğlu; Ercan Yuvanç; Üçler Kısa; Mahi Balcı; Ertan Batislam; Erdal Yılmaz
Journal:  Turk J Urol       Date:  2018-11-19
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.